PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Riad Salem, MD, MBA, Mark Yarchoan, MD - Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease Apr 13, 2023

Show notes

Go online to PeerView.com/WEZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern care of hepatocellular carcinoma (HCC) is increasingly reliant on collaboration between interventional radiology and oncology to select, combine, sequence, and transition between therapy options. In this activity, based on a recent webcast event, case-based discussions are used to explore best practices for managing patients through interdisciplinary collaboration. Experts discuss innovative immunotherapy and locoregional therapy options in earlier-stage disease, the transition to systemic therapy in advanced disease, and explore the latest clinical and safety data in immunotherapy-antiangiogenic regimens, dual checkpoint inhibitor approaches, and newer single-agent immune options. Upon completion of this activity, participants should be better able to: Cite current evidence supporting immunotherapy-based platforms in advanced and intermediate HCC; Integrate immunotherapy platforms into team-based, multidisciplinary management of intermediate- and advanced-stage HCC, including via clinical trial enrollment when appropriate; and Address safety, dosing, care coordination, and therapy delivery considerations when treating patients with HCC using multimodal management options.

Neal K. Lakdawala, MD, Anjali Tiku Owens, MD - Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment Apr 06, 2023

Show notes

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Robert C. Green, MD, MPH - Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients? Apr 06, 2023

Show notes

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team.

Stephanie Lee, MD, MPH - Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease Apr 06, 2023

Show notes

Go online to PeerView.com/CJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Preventing and managing graft-versus-host disease (GVHD) remains a significant problem in the post–allogeneic hematopoietic stem cell transplant (HCT) setting. Can a wide range of unique treatment modalities, including costimulatory compounds, targeted agents, and engineered cell therapy, challenge long-standing management protocols in this setting? Find out in this activity, based on a recent live symposium, which features an overview of available and emerging therapeutic options for modern GVHD management as a means to extend the benefits of HCT and provide more effective prophylaxis and treatment. Upon completion of this activity, participants should be better able to: Summarize current safety/efficacy evidence supporting the use of novel therapeutics for prophylaxis or treatment of acute or chronic graft-versus-host-disease (GVHD) in the post-transplant setting; Develop management plans with novel and emerging therapeutics for the prophylaxis of GVHD in the post-transplant setting, based on current evidence and practice guidelines; and Integrate novel and emerging therapies into safe, personalized treatment plans for the management of acute or chronic GVHD, including novel combinatorial strategies and/or options for second-line management.

Paul Kwo, MD, AGAF, FACG, FAASLD - HBV Is Primary! Your Role in the "Call to Action" to Eliminate Viral Hepatitis By 2030 Apr 06, 2023

Show notes

Go online to PeerView.com/AYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses the importance of early detection of hepatitis B virus (HBV) infection and presents current and evolving screening, vaccination, and treatment guidelines. The expert emphasizes the role of primary care providers in managing patients with chronic HBV and in helping to reach the WHO goal of eliminating viral hepatitis as a public health threat by 2030 through vaccination, screening, and patient education. Finally, the expert clarifies when patients with chronic HBV infection should be referred for specialty care. Upon completion of this activity, participants should be better able to: Describe the burden and consequences of HBV infection and how chronic HBV can lead to end-stage liver disease and hepatocellular carcinoma; Identify patients who should be screened for HBV, which tests should be ordered, and how to interpret the results; Manage HBV in the primary care setting in accordance with current evidence and guidelines, recognizing patients who require specialty care referral; and Implement patient-centered and culturally relevant strategies to promote adherence to HBV treatment and retention in care.

Tricia Cottrell, MD, PhD, Lynette M. Sholl, MD - Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment Apr 06, 2023

Show notes

Go online to PeerView.com/GNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the continued expansion of the cancer immunotherapy arsenal, reliable biomarkers to identify patients most likely to benefit from specific agents or combinations have become crucial. Predictive biomarkers such as measurement of PD-L1 expression and assessment of MSI/MMR or TMB status have an established role in some tumor types and settings, but a number of challenges related to testing and interpretation of results persist, and significant improvements are needed. There is also a need for ways to assess response to immunotherapies as they transition to early-stage, curative-intent settings as part of perioperative multimodal management of solid malignancies. Recently, pathologic response assessment has emerged as a potential new gold standard for measurement of impact of neoadjuvant immunotherapy. However, there has been limited guidance on how to define pathologic response, process and evaluate resected specimens, and report and apply assessment results in the settings of clinical trials and practice. This PeerView educational activity, based on a recent live symposium, focuses on current and emerging immunotherapy biomarkers, the rationale for and practicalities of biomarker testing as a guide for immunotherapy selection for different solid tumors, and the nuances of pathologic response assessment after neoadjuvant immunotherapy. Additionally, practical guidance is provided to help multidisciplinary coordination of care based on biomarker testing and pathologic response assessment so that more patients receive personalized immunotherapy and experience improved outcomes. Upon completion of this activity, participants should be better able to: Explain the evidence and rationale for the role of biomarkers to predict and assess response to cancer immunotherapy in metastatic and resectable solid malignancies; Conduct cancer immunotherapy biomarker testing and pathologic response assessment congruent with the latest evidence, requirements, and recommendations; and Personalize cancer immunotherapy treatment and response assessment by collaborating with multidisciplinary care team members to optimally select and interpret biomarkers.

John Ravits, MD, FAAN - Hope Is on the Horizon for Patients With ALS: Overcoming Diagnostic Difficulties and Exploring Novel Emerging Therapeutic Approaches Apr 06, 2023

Show notes

Go online to PeerView.com/ZXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the importance of early detection and diagnosis of ALS, advances in genetic testing and biomarker development, and current and emerging therapeutic approaches for patients with ALS, as well as the benefits of employing a multidisciplinary approach in managing patients with ALS. Upon completion of this activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis; Apply established criteria to detect and diagnose patients with ALS early in the disease course; Assess key data sets on contemporary and emerging evidence-based treatment options to manage symptoms and improve the quality of life of patients with ALS; and Employ a multidisciplinary team-based approach to optimize the management of ALS based on the individual needs and preferences of each patient.

Sean Pokorney, MD, MBA - Episode 4. The Fear Factor: Mitigating Patients’ Concerns About Anticoagulation Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 5. State-of-the-Art Treatment: Catching Up With Current Guidelines Apr 05, 2023

Show notes

Sean Pokorney, MD, MBA - Episode 2. Profiles in Comorbidity: Identifying Who Is at High Risk Apr 05, 2023

Show notes

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected